首页 > 最新文献

International Journal of Surgical Oncology最新文献

英文 中文
Total Mesorectal Excision with or without Lateral Pelvic Lymph Node Dissection in Rectal Cancer. 在直肠癌中进行全中胚层切除术,同时进行或不进行侧盆腔淋巴结清扫术
IF 1.5 Q4 ONCOLOGY Pub Date : 2023-12-26 eCollection Date: 2023-01-01 DOI: 10.1155/2023/6653624
Mohamed Yehia Elbarmelgi, Ahmed Mohamed Abdelaal, Osama Refaie, Mohamed Tamer, Ali Ahmed Shafik

Results: Incidence of local recurrence was slightly higher in Group A (8.7%) than in Group B (4.3%) but was not statistically significant. There was no statistical significance between both groups regarding distant metastasis (8.7% in Group A and 13% in Group B). Urinary and sexual dysfunctions were higher in Group B (26.1%) compared to those in Group A (21.7%) but were not statistically significant. The incidence of lateral pelvic lymph node metastasis was 30.4%. Also, intraoperative blood loss was higher and operative time was longer in Group B which was statistically significant (P value <0.001).

Conclusion: Our conclusion was that prophylactic addition of LPLD to TME was not associated with a statistically significant decrease in the risk of local recurrence or distant metastasis in patients with rectal cancer, although it was numerically better. LPLD is associated with longer operative time and higher intraoperative blood loss.

结果A 组的局部复发率(8.7%)略高于 B 组(4.3%),但无统计学意义。两组的远处转移率(A 组为 8.7%,B 组为 13%)无统计学意义。与 A 组(21.7%)相比,B 组的排尿和性功能障碍发生率更高(26.1%),但无统计学意义。盆腔侧淋巴结转移的发生率为 30.4%。此外,B 组的术中失血量更高,手术时间更长,差异有统计学意义(P 值 结论):我们的结论是,在 TME 中预防性增加 LPLD 并不能显著降低直肠癌患者的局部复发或远处转移风险,尽管在数量上更胜一筹。LPLD与更长的手术时间和更高的术中失血量有关。
{"title":"Total Mesorectal Excision with or without Lateral Pelvic Lymph Node Dissection in Rectal Cancer.","authors":"Mohamed Yehia Elbarmelgi, Ahmed Mohamed Abdelaal, Osama Refaie, Mohamed Tamer, Ali Ahmed Shafik","doi":"10.1155/2023/6653624","DOIUrl":"10.1155/2023/6653624","url":null,"abstract":"<p><strong>Results: </strong>Incidence of local recurrence was slightly higher in Group A (8.7%) than in Group B (4.3%) but was not statistically significant. There was no statistical significance between both groups regarding distant metastasis (8.7% in Group A and 13% in Group B). Urinary and sexual dysfunctions were higher in Group B (26.1%) compared to those in Group A (21.7%) but were not statistically significant. The incidence of lateral pelvic lymph node metastasis was 30.4%. Also, intraoperative blood loss was higher and operative time was longer in Group B which was statistically significant (<i>P</i> value <0.001).</p><p><strong>Conclusion: </strong>Our conclusion was that prophylactic addition of LPLD to TME was not associated with a statistically significant decrease in the risk of local recurrence or distant metastasis in patients with rectal cancer, although it was numerically better. LPLD is associated with longer operative time and higher intraoperative blood loss.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2023 ","pages":"6653624"},"PeriodicalIF":1.5,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10761226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139088930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and Risk Factors of Thyroid Malignancy in Patients with Toxic Nodular Goiter 中毒性结节性甲状腺肿患者甲状腺恶性肿瘤的发生率及危险因素分析
IF 1.5 Q4 ONCOLOGY Pub Date : 2022-05-23 DOI: 10.1155/2022/1054297
T. Mohamed, A. Sultan, M. Tag El-Din, Ahmed A. Elfattah Mostafa, M. Nafea, Abd-Elfattah Kalmoush, Mohammed Shaaban Nassar, Mohamad Adel Abdalgaleel, A. Hegab, A. H. Ibrahim, Mohamad Baheeg
Background Although hyperfunctioning thyroid disorders were thought to be protective against malignancy, some recent studies reported a high incidence of incidentally discovered cancer in patients with hyperfunctioning benign thyroid disorders. We performed this study to estimate the incidence and predictors of malignant thyroid disease in patients with toxic nodular goiter (TNG). Patients and Methods. The data of 98 patients diagnosed with TNG were reviewed (including toxic multinodular goiter SMNG and single toxic nodule STN). The collected data included patients age, gender, systemic comorbidities, family history of thyroid malignancy, previous neck radiation, type of disease (multinodular or single), size of the dominant nodule by the US, operative time, and detection of significant lymph nodes during operation. Based on the histopathological analysis, the cases were allocated into benign and malignant groups. Results Malignancy was detected in 21 patients (21.43%). Although age distribution was comparable between the two groups, males showed a significant increase in association with malignancy. Medical comorbidities and family history of cancer did not differ between the two groups. However, TMNG showed a statistically higher prevalence in the malignant group. Operative data, including operative time and lymph node detection, were comparable between the two groups. On regression analysis, both male gender and TMNG were significant predictors of malignancy. Conclusion The presence of thyroid hyperfunction is not a protective factor against malignancy, as malignancy was detected in about 1/5 of cases. Male gender and TMNG were significant risk factors of malignancy in such patients.
虽然甲状腺功能亢进被认为对恶性肿瘤有保护作用,但最近的一些研究报道,良性甲状腺功能亢进患者偶然发现癌症的发生率很高。我们进行这项研究是为了估计中毒性结节性甲状腺肿(TNG)患者恶性甲状腺疾病的发生率和预测因素。患者和方法。本文回顾了98例诊断为TNG的患者的资料(包括毒性多结节性甲状腺肿SMNG和单一毒性结节性甲状腺肿STN)。收集的资料包括患者的年龄、性别、全身性合并症、甲状腺恶性家族史、既往颈部放疗、疾病类型(多结节或单发)、超声检查优势结节大小、手术时间、术中有无明显淋巴结。根据组织病理学分析,将病例分为良性组和恶性组。结果恶性肿瘤21例(21.43%)。尽管两组之间的年龄分布相似,但男性与恶性肿瘤的相关性显著增加。医学合并症和癌症家族史在两组之间没有差异。然而,TMNG在恶性组的患病率在统计学上更高。两组的手术数据,包括手术时间和淋巴结检测,具有可比性。在回归分析中,男性性别和TMNG都是恶性肿瘤的显著预测因子。结论甲状腺功能亢进并不是预防恶性肿瘤的保护因素,约1/5的病例可检出恶性肿瘤。男性和TMNG是此类患者发生恶性肿瘤的重要危险因素。
{"title":"Incidence and Risk Factors of Thyroid Malignancy in Patients with Toxic Nodular Goiter","authors":"T. Mohamed, A. Sultan, M. Tag El-Din, Ahmed A. Elfattah Mostafa, M. Nafea, Abd-Elfattah Kalmoush, Mohammed Shaaban Nassar, Mohamad Adel Abdalgaleel, A. Hegab, A. H. Ibrahim, Mohamad Baheeg","doi":"10.1155/2022/1054297","DOIUrl":"https://doi.org/10.1155/2022/1054297","url":null,"abstract":"Background Although hyperfunctioning thyroid disorders were thought to be protective against malignancy, some recent studies reported a high incidence of incidentally discovered cancer in patients with hyperfunctioning benign thyroid disorders. We performed this study to estimate the incidence and predictors of malignant thyroid disease in patients with toxic nodular goiter (TNG). Patients and Methods. The data of 98 patients diagnosed with TNG were reviewed (including toxic multinodular goiter SMNG and single toxic nodule STN). The collected data included patients age, gender, systemic comorbidities, family history of thyroid malignancy, previous neck radiation, type of disease (multinodular or single), size of the dominant nodule by the US, operative time, and detection of significant lymph nodes during operation. Based on the histopathological analysis, the cases were allocated into benign and malignant groups. Results Malignancy was detected in 21 patients (21.43%). Although age distribution was comparable between the two groups, males showed a significant increase in association with malignancy. Medical comorbidities and family history of cancer did not differ between the two groups. However, TMNG showed a statistically higher prevalence in the malignant group. Operative data, including operative time and lymph node detection, were comparable between the two groups. On regression analysis, both male gender and TMNG were significant predictors of malignancy. Conclusion The presence of thyroid hyperfunction is not a protective factor against malignancy, as malignancy was detected in about 1/5 of cases. Male gender and TMNG were significant risk factors of malignancy in such patients.","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48926219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
High CD44 Immunoexpression Correlates with Poor Overall Survival: Assessing the Role of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma Patients from the High-Risk Population of Pakistan CD44免疫表达高与总体生存率低相关:评估癌症干细胞标记物在巴基斯坦高危人群口腔鳞状细胞癌患者中的作用
IF 1.5 Q4 ONCOLOGY Pub Date : 2022-03-07 DOI: 10.1155/2022/9990489
Y. Adnan, S. M. A. Ali, H. Farooqui, H. A. Kayani, Romana Idrees, M. S. Awan
Oral squamous cell carcinoma (OSCC) is a top-ranked cancer in the Pakistani population, and patient survival has remained unchanged at ∼50% for several decades. Recent advances have claimed that a subset of tumour cells, called cancer stem cells (CSCs), are responsible for tumour progression, treatment resistance, and metastasis, which leads to a poor prognosis. This study investigated the impact of CSC markers expression on overall survival (OS) and disease-free survival (DFS) of OSCC patients. Materials and Methods. Immunohistochemistry was used to evaluate CD44, CD133, L1CAM, and SOX2 expression in a well-characterized cohort of 100 Pakistani patients with primary treatment naïve OSCC. The immunoreactivity for each marker was correlated with patient clinicopathologic characteristics, oral cancer risk chewing habits, and survival. The minimum follow-up time for all patients was five years, and survival estimates were calculated using the Kaplan–Meier method and Cox proportional hazards model. Results. In this cohort of 100 patients, there were 57 males and 43 females. The median OS and DFS time durations observed were 64 and 52.5 months, respectively. Positive expression for CD44, CD133, L1CAM, and SOX2 was observed in 33%, 23%, 41%, and 63% of patients. High CD44 expression correlated with decreased OS (P=0.047) but did not influence DFS. However, CD133, L1CAM, and SOX2 had no effect on either OS or DFS. Tonsils, nodal involvement, and AJCC stage were independent predictors of worse OS and DFS both. Conclusion. Of the CSC markers investigated here, only CD44 was a predictor for poor OS. CD44 was also associated with advanced AJCC and T stages. Interestingly, CD133 was significantly lower in patients who habitually consumed oral cancer risk factors.
口腔鳞状细胞癌(OSCC)是巴基斯坦人口中排名第一的癌症,几十年来患者存活率一直保持在约50%不变。最近的进展表明,一种被称为癌症干细胞(CSCs)的肿瘤细胞亚群负责肿瘤进展、治疗耐药性和转移,从而导致预后不良。本研究调查了CSC标志物表达对OSCC患者总生存期(OS)和无病生存期(DFS)的影响。材料和方法。免疫组织化学用于评估CD44、CD133、L1CAM和SOX2在一个由100名巴基斯坦初级治疗幼稚OSCC患者组成的具有良好特征的队列中的表达。每个标志物的免疫反应性与患者的临床病理特征、口腔癌症风险咀嚼习惯和存活率相关。所有患者的最短随访时间为5年,使用Kaplan–Meier方法和Cox比例风险模型计算生存率估计值。后果在这个由100名患者组成的队列中,有57名男性和43名女性。观察到的OS和DFS的中位持续时间分别为64个月和52.5个月。在33%、23%、41%和63%的患者中观察到CD44、CD133、L1CAM和SOX2的阳性表达。CD44高表达与OS降低相关(P=0.047),但不影响DFS。然而,CD133、L1CAM和SOX2对OS或DFS均无影响。扁桃体、淋巴结受累和AJCC分期是OS和DFS恶化的独立预测因素。结论在这里研究的CSC标志物中,只有CD44是OS不良的预测因素。CD44也与晚期AJCC和T分期有关。有趣的是,习惯性服用口服癌症危险因素的患者CD133显著降低。
{"title":"High CD44 Immunoexpression Correlates with Poor Overall Survival: Assessing the Role of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma Patients from the High-Risk Population of Pakistan","authors":"Y. Adnan, S. M. A. Ali, H. Farooqui, H. A. Kayani, Romana Idrees, M. S. Awan","doi":"10.1155/2022/9990489","DOIUrl":"https://doi.org/10.1155/2022/9990489","url":null,"abstract":"Oral squamous cell carcinoma (OSCC) is a top-ranked cancer in the Pakistani population, and patient survival has remained unchanged at ∼50% for several decades. Recent advances have claimed that a subset of tumour cells, called cancer stem cells (CSCs), are responsible for tumour progression, treatment resistance, and metastasis, which leads to a poor prognosis. This study investigated the impact of CSC markers expression on overall survival (OS) and disease-free survival (DFS) of OSCC patients. Materials and Methods. Immunohistochemistry was used to evaluate CD44, CD133, L1CAM, and SOX2 expression in a well-characterized cohort of 100 Pakistani patients with primary treatment naïve OSCC. The immunoreactivity for each marker was correlated with patient clinicopathologic characteristics, oral cancer risk chewing habits, and survival. The minimum follow-up time for all patients was five years, and survival estimates were calculated using the Kaplan–Meier method and Cox proportional hazards model. Results. In this cohort of 100 patients, there were 57 males and 43 females. The median OS and DFS time durations observed were 64 and 52.5 months, respectively. Positive expression for CD44, CD133, L1CAM, and SOX2 was observed in 33%, 23%, 41%, and 63% of patients. High CD44 expression correlated with decreased OS (P=0.047) but did not influence DFS. However, CD133, L1CAM, and SOX2 had no effect on either OS or DFS. Tonsils, nodal involvement, and AJCC stage were independent predictors of worse OS and DFS both. Conclusion. Of the CSC markers investigated here, only CD44 was a predictor for poor OS. CD44 was also associated with advanced AJCC and T stages. Interestingly, CD133 was significantly lower in patients who habitually consumed oral cancer risk factors.","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2022 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42541242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
The Beneficial Impact of Intraoperative Ultrasound on Resection Margin Status during Breast Conserving Surgery. 保乳手术中术中超声对切除缘状态的有益影响。
IF 1.5 Q4 ONCOLOGY Pub Date : 2022-01-01 DOI: 10.1155/2022/2268821
Osama Almezaien, Ahmed Mohamed Eldeeb, Abdelfattah Kalmoush, Mohamed Shaaban Nassar, Tarek Zaghlol Mohamed, Mohamed Sobhy Shaaban, Mohamed Ibrahim Henish, Sobhy Teama, Saed Abdolmonem Elgohary Khalafallah, Lofty A Ibrahim

Background: Surgical resection with clear surgical cut margins is the mainstay of managing malignant breast neoplasms. Multiple techniques have been suggested to enhance resection status during breast-conserving surgery (BCS), including intraoperative ultrasonography (IOUS). Herein, we conducted the current investigation to reveal the benefit of IOUS on the achievement of R0 resection. Patients and Methods. This retrospective investigation included 140 patients who underwent BCS. They were divided into two groups: the IOUS group (40 cases) and the control group (100 cases). Our primary objective was to determine the free resection margin status (R0).

Results: Both study groups expressed statistically comparable demographic and clinical data. Additionally, histopathological examination revealed no significant difference between the two groups regarding the tumor type, stage, or grade. Nonetheless, the R0 resection margin was more frequently encountered in association with IOUS application (97.5% compared to 79% in the control group), and that difference was statistically significant (p=0.007).

Conclusion: The application of IOUS has a significant beneficial impact on the outcomes of BCS. It is associated with a marked decline in positive resection margins, and its application should be encouraged in the breast oncological practice.

背景:手术切除和清晰的切缘是治疗乳腺恶性肿瘤的主要方法。在保乳手术(BCS)中,有多种技术被建议提高切除状态,包括术中超声检查(IOUS)。在此,我们进行了当前的调查,以揭示欠条对实现R0切除的好处。患者和方法。这项回顾性调查包括140例接受BCS的患者。他们被分为两组:欠条组(40例)和对照组(100例)。我们的主要目的是确定自由切除边缘状态(R0)。结果:两个研究组的人口统计学和临床数据具有可比性。此外,组织病理学检查显示两组在肿瘤类型、分期或分级方面无显著差异。尽管如此,R0切除边缘与白条应用相关的情况更频繁(97.5%,对照组79%),差异具有统计学意义(p=0.007)。结论:应用欠条对BCS的预后有显著的有益影响。它与阳性切除边缘的显著下降有关,应鼓励其在乳腺肿瘤实践中的应用。
{"title":"The Beneficial Impact of Intraoperative Ultrasound on Resection Margin Status during Breast Conserving Surgery.","authors":"Osama Almezaien,&nbsp;Ahmed Mohamed Eldeeb,&nbsp;Abdelfattah Kalmoush,&nbsp;Mohamed Shaaban Nassar,&nbsp;Tarek Zaghlol Mohamed,&nbsp;Mohamed Sobhy Shaaban,&nbsp;Mohamed Ibrahim Henish,&nbsp;Sobhy Teama,&nbsp;Saed Abdolmonem Elgohary Khalafallah,&nbsp;Lofty A Ibrahim","doi":"10.1155/2022/2268821","DOIUrl":"https://doi.org/10.1155/2022/2268821","url":null,"abstract":"<p><strong>Background: </strong>Surgical resection with clear surgical cut margins is the mainstay of managing malignant breast neoplasms. Multiple techniques have been suggested to enhance resection status during breast-conserving surgery (BCS), including intraoperative ultrasonography (IOUS). Herein, we conducted the current investigation to reveal the benefit of IOUS on the achievement of R0 resection. <i>Patients and Methods</i>. This retrospective investigation included 140 patients who underwent BCS. They were divided into two groups: the IOUS group (40 cases) and the control group (100 cases). Our primary objective was to determine the free resection margin status (R0).</p><p><strong>Results: </strong>Both study groups expressed statistically comparable demographic and clinical data. Additionally, histopathological examination revealed no significant difference between the two groups regarding the tumor type, stage, or grade. Nonetheless, the R0 resection margin was more frequently encountered in association with IOUS application (97.5% compared to 79% in the control group), and that difference was statistically significant (<i>p</i>=0.007).</p><p><strong>Conclusion: </strong>The application of IOUS has a significant beneficial impact on the outcomes of BCS. It is associated with a marked decline in positive resection margins, and its application should be encouraged in the breast oncological practice.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2022 ","pages":"2268821"},"PeriodicalIF":1.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10749212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing Emergent and Elective Colectomy Outcomes in Elderly Patients: A NSQIP Study. 比较老年患者急诊和择期结肠切除术的结果:一项NSQIP研究。
IF 1.5 Q4 ONCOLOGY Pub Date : 2021-12-06 eCollection Date: 2021-01-01 DOI: 10.1155/2021/9990434
Mostapha El Edelbi, Ibrahim Abdallah, Rola F Jaafar, Hani Tamim, Samer Deeba, Samer Doughan

Introduction: With the increasing prevalence of colorectal cancer (CRC) worldwide, especially in the elderly, and the variability between physiological and chronological age and its impact on functional status, acute symptoms leading to emergent surgery due to colorectal malignancy may lead to increased morbidity and mortality. The aim of this study is to identify the outcome differences of elective vs. emergent open colectomy in patients above 80 years.

Methods: The National Surgical Quality Improvement Program (NSQIP) database was reviewed from 2010 to 2014 for open colectomy based on CPT codes. Comparison between groups was done based on the clinical context at presentation as elective or emergent surgery. Data were analyzed using SAS.

Results: Elective colectomies were performed in 8289 (70.8%) vs. emergent colectomies in 3409 (29.1%). Emergent colectomy patients had higher American Society of Anesthesiologists (ASA) preoperative classification III-IV, 1429 (42.0%) and 224 (6.6%), vs. 1238 (14.9%) and 21 (0.2%) in elective colectomy patients (p < 0.0001). Emergent colectomy patients had more comorbidities such as chronic obstructive pulmonary disorder (493 (14.5%) vs. 796 (9.6%)), congestive heart failure (206 (6.0%) vs. 310 (3.8%)), dialysis (106 (3.1%) vs. 56 (0.7%)), and acute renal failure (166 (4.9%) vs. 46 (0.6%)) (p < 0.0001), respectively. Postoperative morbidity and mortality were significantly higher in emergent colectomy (1651 (48.4%) and 872 (25.6%)) vs. elective colectomy (1859 (22.4%) and 567 (6.8%)) (p < 0.0001), respectively.

Conclusion: Emergent open colectomy in elderly patients carries a higher risk of morbidity and mortality when compared to elective open colectomy with risk factors being higher ASA classification and more comorbidities.

导念:随着世界范围内结直肠癌(CRC)患病率的增加,特别是在老年人中,生理年龄和实足年龄之间的差异及其对功能状态的影响,急性症状导致结直肠癌恶性肿瘤紧急手术可能导致发病率和死亡率的增加。本研究的目的是确定80岁以上患者择期和紧急开放式结肠切除术的结果差异。方法:基于CPT编码对2010 - 2014年开放结肠切除术的国家外科质量改进计划(NSQIP)数据库进行检索。两组之间的比较是根据临床情况进行的,作为选择性或紧急手术。数据采用SAS分析。结果:8289例(70.8%)行选择性结肠切除术,3409例(29.1%)行紧急结肠切除术。急诊结肠切除术患者的美国麻醉医师协会(ASA)术前分类为III-IV,分别为1429(42.0%)和224(6.6%),而择期结肠切除术患者的分类为1238(14.9%)和21 (0.2%)(p < 0.0001)。急诊结肠切除术患者有更多的合并症,如慢性阻塞性肺疾病(493例(14.5%)比796例(9.6%))、充血性心力衰竭(206例(6.0%)比310例(3.8%))、透析(106例(3.1%)比56例(0.7%))和急性肾功能衰竭(166例(4.9%)比46例(0.6%))(p < 0.0001)。急诊结肠切除术的术后发病率和死亡率(1651(48.4%)和872(25.6%))明显高于择期结肠切除术(1859(22.4%)和567 (6.8%))(p < 0.0001)。结论:与择期开放式结肠切除术相比,老年患者急诊开放式结肠切除术的发病率和死亡率更高,危险因素为ASA分级更高,合并症更多。
{"title":"Comparing Emergent and Elective Colectomy Outcomes in Elderly Patients: A NSQIP Study.","authors":"Mostapha El Edelbi,&nbsp;Ibrahim Abdallah,&nbsp;Rola F Jaafar,&nbsp;Hani Tamim,&nbsp;Samer Deeba,&nbsp;Samer Doughan","doi":"10.1155/2021/9990434","DOIUrl":"https://doi.org/10.1155/2021/9990434","url":null,"abstract":"<p><strong>Introduction: </strong>With the increasing prevalence of colorectal cancer (CRC) worldwide, especially in the elderly, and the variability between physiological and chronological age and its impact on functional status, acute symptoms leading to emergent surgery due to colorectal malignancy may lead to increased morbidity and mortality. The aim of this study is to identify the outcome differences of elective vs. emergent open colectomy in patients above 80 years.</p><p><strong>Methods: </strong>The National Surgical Quality Improvement Program (NSQIP) database was reviewed from 2010 to 2014 for open colectomy based on CPT codes. Comparison between groups was done based on the clinical context at presentation as elective or emergent surgery. Data were analyzed using SAS.</p><p><strong>Results: </strong>Elective colectomies were performed in 8289 (70.8%) vs. emergent colectomies in 3409 (29.1%). Emergent colectomy patients had higher American Society of Anesthesiologists (ASA) preoperative classification III-IV, 1429 (42.0%) and 224 (6.6%), vs. 1238 (14.9%) and 21 (0.2%) in elective colectomy patients (<i>p</i> < 0.0001). Emergent colectomy patients had more comorbidities such as chronic obstructive pulmonary disorder (493 (14.5%) vs. 796 (9.6%)), congestive heart failure (206 (6.0%) vs. 310 (3.8%)), dialysis (106 (3.1%) vs. 56 (0.7%)), and acute renal failure (166 (4.9%) vs. 46 (0.6%)) (<i>p</i> < 0.0001), respectively. Postoperative morbidity and mortality were significantly higher in emergent colectomy (1651 (48.4%) and 872 (25.6%)) vs. elective colectomy (1859 (22.4%) and 567 (6.8%)) (<i>p</i> < 0.0001), respectively.</p><p><strong>Conclusion: </strong>Emergent open colectomy in elderly patients carries a higher risk of morbidity and mortality when compared to elective open colectomy with risk factors being higher ASA classification and more comorbidities.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"9990434"},"PeriodicalIF":1.5,"publicationDate":"2021-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39729396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Clinicopathological Analysis of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review of 9 Cases. 9例宫颈神经内分泌癌的临床病理分析
IF 1.5 Q4 ONCOLOGY Pub Date : 2021-09-16 eCollection Date: 2021-01-01 DOI: 10.1155/2021/8290659
Saliha Sağnıç, Özer Birge, Mehmet Sait Bakır, Ceyda Karadag, Tayup Şimşek

Aim: To evaluate the clinicopathological features affecting the recurrence and survival of 9 cases of neuroendocrine cancer of the cervix.

Method: We retrospectively analyzed 9 cervical neuroendocrine cancer cases identified among 453 cervical cancer patients between 2004 and 2021 at Akdeniz University Gynecological Oncology Outpatient Clinic. Kaplan-Meier survival analysis was used for progression-free survival (PFS) and overall survival (OS). Mathematical functions of mean, standard deviation, median, Min-Max values, and frequencies were used for descriptive statistics. The categorical data were expressed in numbers and percentages (%).

Results: Nine patients with neuroendocrine histological subtype were selected out of 453 patients diagnosed with cervical cancer (1.98%). The average overall survival time of the patients was 26 months. The 5-year survival rate was 53.3%, while the PFS was 62.5%. The most common subtype was small cell neuroendocrine cancer. Tumours were mostly locally advanced at the time of diagnosis. 3 patients' stage was 1b2, while 4 patients were 2b, 1 patient was 3c2r, and 1 patient was 4b. All tumours showed the immunohistochemical staining properties of neuroendocrine cancer. The main treatment modality applied to our patients was surgery + adjuvant CRT. The most used chemotherapeutic agents were cisplatin/carboplatin and etoposide. Recurrence was found in 3 cases, including 5 deaths.

Conclusion: Neuroendocrine tumour of the cervix is a rare subtype with a poor prognosis. Unfortunately, there is not yet a standard treatment protocol due to the limited number of comparative studies of surgery, chemotherapy, and radiotherapy based treatment schemes.

目的:探讨影响9例宫颈神经内分泌癌复发及生存的临床病理特点。方法:回顾性分析2004年至2021年在Akdeniz大学妇科肿瘤门诊就诊的453例宫颈癌患者中发现的9例宫颈神经内分泌癌。Kaplan-Meier生存分析用于无进展生存期(PFS)和总生存期(OS)。使用均值、标准差、中位数、最小最大值和频率等数学函数进行描述性统计。分类数据以数字和百分比(%)表示。结果:453例宫颈癌患者中,神经内分泌组织学亚型患者9例(1.98%)。患者的平均总生存时间为26个月。5年生存率为53.3%,PFS为62.5%。最常见的亚型是小细胞神经内分泌癌。肿瘤大多在诊断时局部进展。3例为1b2期,4例为2b期,1例为3c2r期,1例为4b期。所有肿瘤均显示神经内分泌癌的免疫组化染色特征。本组患者的主要治疗方式为手术+辅助CRT。使用最多的化疗药物是顺铂/卡铂和依托泊苷。复发3例,死亡5例。结论:宫颈神经内分泌肿瘤是一种少见的肿瘤亚型,预后较差。不幸的是,由于基于手术、化疗和放疗的治疗方案的比较研究数量有限,目前还没有一个标准的治疗方案。
{"title":"Clinicopathological Analysis of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review of 9 Cases.","authors":"Saliha Sağnıç,&nbsp;Özer Birge,&nbsp;Mehmet Sait Bakır,&nbsp;Ceyda Karadag,&nbsp;Tayup Şimşek","doi":"10.1155/2021/8290659","DOIUrl":"https://doi.org/10.1155/2021/8290659","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the clinicopathological features affecting the recurrence and survival of 9 cases of neuroendocrine cancer of the cervix.</p><p><strong>Method: </strong>We retrospectively analyzed 9 cervical neuroendocrine cancer cases identified among 453 cervical cancer patients between 2004 and 2021 at Akdeniz University Gynecological Oncology Outpatient Clinic. Kaplan-Meier survival analysis was used for progression-free survival (PFS) and overall survival (OS). Mathematical functions of mean, standard deviation, median, Min-Max values, and frequencies were used for descriptive statistics. The categorical data were expressed in numbers and percentages (%).</p><p><strong>Results: </strong>Nine patients with neuroendocrine histological subtype were selected out of 453 patients diagnosed with cervical cancer (1.98%). The average overall survival time of the patients was 26 months. The 5-year survival rate was 53.3%, while the PFS was 62.5%. The most common subtype was small cell neuroendocrine cancer. Tumours were mostly locally advanced at the time of diagnosis. 3 patients' stage was 1b2, while 4 patients were 2b, 1 patient was 3c2r, and 1 patient was 4b. All tumours showed the immunohistochemical staining properties of neuroendocrine cancer. The main treatment modality applied to our patients was surgery + adjuvant CRT. The most used chemotherapeutic agents were cisplatin/carboplatin and etoposide. Recurrence was found in 3 cases, including 5 deaths.</p><p><strong>Conclusion: </strong>Neuroendocrine tumour of the cervix is a rare subtype with a poor prognosis. Unfortunately, there is not yet a standard treatment protocol due to the limited number of comparative studies of surgery, chemotherapy, and radiotherapy based treatment schemes.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"8290659"},"PeriodicalIF":1.5,"publicationDate":"2021-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39452544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients. SOX2和AGR2生物标志物作为er阳性乳腺癌患者他莫昔芬耐药的早期预测指标
IF 1.5 Q4 ONCOLOGY Pub Date : 2021-09-15 eCollection Date: 2021-01-01 DOI: 10.1155/2021/9947540
Yomna Zamzam, Yosra Abdelmonem Zamzam, Marwa Aboalsoud, Heba Harras

Background: Despite the undeniable benefit of tamoxifen therapy for ER-positive breast cancer patients, approximately one-third of those patients either do not respond to tamoxifen or develop resistance. Thus, it is a crucial step to identify novel, reliable, and easily detectable biomarkers indicating resistance to this drug.

Objective: The aim of this work is to explore SOX2 and AGR2 biomarker expression in the tumor tissue of ER-positive breast cancer patients in combination with the evaluation of serum AGR2 level of these patients in order to validate these biomarkers as early predictors of tamoxifen resistance.

Methods: This study was conducted on 224 ER-positive breast cancer patients. All patients were primarily subjected to serum AGR2 levelling by ELISA and their breast cancer tissue immunostained for SOX2 and AGR2. After 5 years of follow-up, the patients were divided into 3 groups: group 1 was tamoxifen sensitive and groups 2 and 3 were tamoxifen resistant. Time to failure of tamoxifen treatment was considered the time from the beginning of tamoxifen therapy to the time of discovery of breast cancer recurrence or metastases (in months).

Results: SOX2 and AGR2 biomarkers expression and serum AGR2 level were significantly higher in groups 2 and 3 in comparison to group 1, while the relationship between Her2 neu expression and Ki67 index in the 3 different groups was statistically nonsignificant. Lower SOX2 and AGR2 expression and low AGR2 serum levels in the studied patients of groups 2 and 3 were significantly associated with longer time-to-failure of tamoxifen treatment. According to the ROC curve, the combined use of studied markers validity was with a sensitivity of 100%, specificity of 96%, PPV 96%, and NPV 100% (p < 0.001; AUC: 0.984).

Conclusions: Integrated use of SOX2 and AGR2 biomarkers with serum AGR2 assay holds a promising hope for their future use as predictive markers for early detection of tamoxifen resistance in ER-positive breast cancer patients.

背景:尽管三苯氧胺治疗ER阳性乳腺癌症患者具有不可否认的益处,但约三分之一的患者对三苯氧碱没有反应或出现耐药性。因此,识别新的、可靠的、易于检测的指示对该药物耐药性的生物标志物是至关重要的一步。目的:本工作的目的是结合对ER-阳性乳腺癌症患者血清AGR2水平的评估,探讨SOX2和AGR2生物标志物在肿瘤组织中的表达,以验证这些生物标志物作为他莫昔芬耐药性的早期预测因子。方法:对224例ER阳性乳腺癌症患者进行研究。所有患者首先通过ELISA进行血清AGR2水平测定,并对其癌症组织进行SOX2和AGR2免疫染色。经过5年的随访,患者被分为3组:第一组为三苯氧胺敏感组,第二组和第三组为三苯氧胺耐药性组。三苯氧胺治疗失败的时间被认为是从三苯氧碱治疗开始到发现乳腺癌症复发或转移的时间(以月为单位),而Her2-neu表达与Ki67指数之间的关系在3个不同组中无统计学意义。在第2组和第3组的研究患者中,较低的SOX2和AGR2表达以及较低的AGR2血清水平与三苯氧胺治疗失败的时间较长显著相关。根据ROC曲线,联合使用所研究的标志物的有效性具有100%的敏感性、96%的特异性、96%的PPV和100%的NPV(p<0.001;AUC:0.984)。
{"title":"The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients.","authors":"Yomna Zamzam,&nbsp;Yosra Abdelmonem Zamzam,&nbsp;Marwa Aboalsoud,&nbsp;Heba Harras","doi":"10.1155/2021/9947540","DOIUrl":"10.1155/2021/9947540","url":null,"abstract":"<p><strong>Background: </strong>Despite the undeniable benefit of tamoxifen therapy for ER-positive breast cancer patients, approximately one-third of those patients either do not respond to tamoxifen or develop resistance. Thus, it is a crucial step to identify novel, reliable, and easily detectable biomarkers indicating resistance to this drug.</p><p><strong>Objective: </strong>The aim of this work is to explore SOX2 and AGR2 biomarker expression in the tumor tissue of ER-positive breast cancer patients in combination with the evaluation of serum AGR2 level of these patients in order to validate these biomarkers as early predictors of tamoxifen resistance.</p><p><strong>Methods: </strong>This study was conducted on 224 ER-positive breast cancer patients. All patients were primarily subjected to serum AGR2 levelling by ELISA and their breast cancer tissue immunostained for SOX2 and AGR2. After 5 years of follow-up, the patients were divided into 3 groups: group 1 was tamoxifen sensitive and groups 2 and 3 were tamoxifen resistant. Time to failure of tamoxifen treatment was considered the time from the beginning of tamoxifen therapy to the time of discovery of breast cancer recurrence or metastases (in months).</p><p><strong>Results: </strong>SOX2 and AGR2 biomarkers expression and serum AGR2 level were significantly higher in groups 2 and 3 in comparison to group 1, while the relationship between Her2 neu expression and Ki67 index in the 3 different groups was statistically nonsignificant. Lower SOX2 and AGR2 expression and low AGR2 serum levels in the studied patients of groups 2 and 3 were significantly associated with longer time-to-failure of tamoxifen treatment. According to the ROC curve, the combined use of studied markers validity was with a sensitivity of 100%, specificity of 96%, PPV 96%, and NPV 100% (<i>p</i> < 0.001; AUC: 0.984).</p><p><strong>Conclusions: </strong>Integrated use of SOX2 and AGR2 biomarkers with serum AGR2 assay holds a promising hope for their future use as predictive markers for early detection of tamoxifen resistance in ER-positive breast cancer patients.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"9947540"},"PeriodicalIF":1.5,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39452545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma. KRAS基因突变对结直肠癌腹膜转移患者生存的预后价值。
IF 1.5 Q4 ONCOLOGY Pub Date : 2021-09-13 eCollection Date: 2021-01-01 DOI: 10.1155/2021/3946875
Manuel Díez-Alonso, Fernando Mendoza-Moreno, Remedios Gómez-Sanz, Belén Matías-García, Enrique Ovejero-Merino, Raquel Molina, Sonia Soto-Schütte, Alberto San Juan, Alberto Gutierrez-Calvo

Objective: The main objective of the study was to determine the effect of the presence of mutation in the KRAS gene on the survival in patients with colorectal cancer (CRC) and peritoneal metastases (PM).

Materials and methods: A retrospective cohort study was performed. Patients diagnosed with CRC with synchronous or metachronous PM between January 2006 and December 2019 were included. Data on the histopathological, clinical, and treatment factors were collected. The effect of each variable on survival was evaluated by Cox regression.

Results: A total of 149 patients were included (64 women (43%) and 85 men (57%); mean age, 63 years). The long-term survival rate at 36 months was 24% (median, 21 months). KRAS mutation was detected in 75 patients (50.3%). Kaplan-Meier analysis estimated that likelihood of survival was higher in patients with wild-type KRAS tumours (35%) than in mutated-type KRAS (14%) (median: 28 vs. 15, respectively) (P=0.001). Within the categories into which the peritoneal cancer index (PCI) was classified, survival at 36 months depended on the KRAS status. Survival in wild-type KRAS tumours with PCI 1-10 was 71% and with PCI 11-20 was 26%, while in mutant-type KRAS tumours, survival was 41% and 4%, respectively (P=0.025). In the multiple regression analysis, the KRAS mutation was revealed to have an independent prognostic value (HR: 2.144; 95% CI: 1.342-3.424).

Conclusion: The mutational status of the KRAS gene has demonstrated a strong association with survival and prognostic utility in patients with CRC with PM.

目的:本研究的主要目的是确定KRAS基因突变对结直肠癌(CRC)和腹膜转移(PM)患者生存的影响。材料和方法:进行回顾性队列研究。研究纳入了2006年1月至2019年12月期间诊断为伴有同步或异时性PM的结直肠癌患者。收集组织病理学、临床和治疗因素的数据。采用Cox回归评价各变量对生存率的影响。结果:共纳入149例患者,其中女性64例(43%),男性85例(57%);平均年龄63岁)。36个月的长期生存率为24%(中位21个月)。KRAS突变75例(50.3%)。Kaplan-Meier分析估计,野生型KRAS患者的生存可能性(35%)高于突变型KRAS患者(14%)(中位数分别为28 vs 15) (P=0.001)。在腹膜癌指数(PCI)的分类中,36个月的生存率取决于KRAS状态。PCI 1-10野生型KRAS肿瘤的生存率为71%,PCI 11-20野生型KRAS肿瘤的生存率为26%,而突变型KRAS肿瘤的生存率分别为41%和4% (P=0.025)。在多元回归分析中,KRAS突变具有独立的预后价值(HR: 2.144;95% ci: 1.342-3.424)。结论:KRAS基因的突变状态与结直肠癌合并PM患者的生存和预后密切相关。
{"title":"Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma.","authors":"Manuel Díez-Alonso,&nbsp;Fernando Mendoza-Moreno,&nbsp;Remedios Gómez-Sanz,&nbsp;Belén Matías-García,&nbsp;Enrique Ovejero-Merino,&nbsp;Raquel Molina,&nbsp;Sonia Soto-Schütte,&nbsp;Alberto San Juan,&nbsp;Alberto Gutierrez-Calvo","doi":"10.1155/2021/3946875","DOIUrl":"https://doi.org/10.1155/2021/3946875","url":null,"abstract":"<p><strong>Objective: </strong>The main objective of the study was to determine the effect of the presence of mutation in the KRAS gene on the survival in patients with colorectal cancer (CRC) and peritoneal metastases (PM).</p><p><strong>Materials and methods: </strong>A retrospective cohort study was performed. Patients diagnosed with CRC with synchronous or metachronous PM between January 2006 and December 2019 were included. Data on the histopathological, clinical, and treatment factors were collected. The effect of each variable on survival was evaluated by Cox regression.</p><p><strong>Results: </strong>A total of 149 patients were included (64 women (43%) and 85 men (57%); mean age, 63 years). The long-term survival rate at 36 months was 24% (median, 21 months). KRAS mutation was detected in 75 patients (50.3%). Kaplan-Meier analysis estimated that likelihood of survival was higher in patients with wild-type KRAS tumours (35%) than in mutated-type KRAS (14%) (median: 28 vs. 15, respectively) (<i>P</i>=0.001). Within the categories into which the peritoneal cancer index (PCI) was classified, survival at 36 months depended on the KRAS status. Survival in wild-type KRAS tumours with PCI 1-10 was 71% and with PCI 11-20 was 26%, while in mutant-type KRAS tumours, survival was 41% and 4%, respectively (<i>P</i>=0.025). In the multiple regression analysis, the KRAS mutation was revealed to have an independent prognostic value (HR: 2.144; 95% CI: 1.342-3.424).</p><p><strong>Conclusion: </strong>The mutational status of the KRAS gene has demonstrated a strong association with survival and prognostic utility in patients with CRC with PM.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"3946875"},"PeriodicalIF":1.5,"publicationDate":"2021-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39443833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Gastrointestinal Stromal Tumor (GIST) and Synchronous Intra-Abdominal Liposarcoma: A Report of Two Rare Cases and Literature Review. 胃肠道间质瘤合并腹腔内脂肪肉瘤2例报告并文献复习。
IF 1.5 Q4 ONCOLOGY Pub Date : 2021-09-01 eCollection Date: 2021-01-01 DOI: 10.1155/2021/2626635
Alexandros Diamantis, Athina A Samara, Ioannis Baloyiannis, Dimitrios Symeonidis, Andreas-Marios Diamantis, Maria Tolia, Konstantinos Bouliaris, Georgios Koukoulis, Konstantinos Tepetes

Introduction: Gastrointestinal stromal tumors (GISTs) quite frequently occur synchronously with other malignancies, with most cases being adenocarcinomas. GISTs and liposarcomas are both of mesenchymal origin, and their coexistence is extremely rare.

Methods: We conducted a review of the current literature regarding the synchronous occurrence of GISTs and intra-abdominal liposarcomas. An electronic search of the literature was undertaken using MEDLINE (database provider PubMed). Furthermore, we present the first described case of an 86-year-old male with a GIST and synchronous liposarcoma, both located in the stomach, as well as a 66-year-old male with a gastric GIST and concurrent retroperitoneal liposarcoma.

Results: A total of 5 cases of synchronous GIST and intra-abdominal liposarcoma have been reported in the literature to date, with the most recent cases included in the present study.

Conclusion: Further research is required to explain any possible correlation in the coexistence of these different neoplasms of the same origin. Meanwhile, R0 resection of both tumors remains the treatment of choice.

胃肠道间质瘤(gist)常与其他恶性肿瘤同时发生,以腺癌为主。gist和脂肪肉瘤均为间质起源,两者共存极为罕见。方法:我们对目前有关胃肠道间质瘤和腹腔内脂肪肉瘤同时发生的文献进行了回顾。使用MEDLINE(数据库提供商PubMed)对文献进行电子检索。此外,我们报告了第一例86岁男性间质间质瘤和同步脂肪肉瘤,均位于胃,以及66岁男性胃间质间质瘤和并发腹膜后脂肪肉瘤。结果:迄今为止,文献中共报道了5例同步GIST和腹腔内脂肪肉瘤,本研究包括最近的病例。结论:这些同源不同肿瘤共存的相关性有待进一步研究。同时,R0切除两种肿瘤仍是首选的治疗方法。
{"title":"Gastrointestinal Stromal Tumor (GIST) and Synchronous Intra-Abdominal Liposarcoma: A Report of Two Rare Cases and Literature Review.","authors":"Alexandros Diamantis,&nbsp;Athina A Samara,&nbsp;Ioannis Baloyiannis,&nbsp;Dimitrios Symeonidis,&nbsp;Andreas-Marios Diamantis,&nbsp;Maria Tolia,&nbsp;Konstantinos Bouliaris,&nbsp;Georgios Koukoulis,&nbsp;Konstantinos Tepetes","doi":"10.1155/2021/2626635","DOIUrl":"https://doi.org/10.1155/2021/2626635","url":null,"abstract":"<p><strong>Introduction: </strong>Gastrointestinal stromal tumors (GISTs) quite frequently occur synchronously with other malignancies, with most cases being adenocarcinomas. GISTs and liposarcomas are both of mesenchymal origin, and their coexistence is extremely rare.</p><p><strong>Methods: </strong>We conducted a review of the current literature regarding the synchronous occurrence of GISTs and intra-abdominal liposarcomas. An electronic search of the literature was undertaken using MEDLINE (database provider PubMed). Furthermore, we present the first described case of an 86-year-old male with a GIST and synchronous liposarcoma, both located in the stomach, as well as a 66-year-old male with a gastric GIST and concurrent retroperitoneal liposarcoma.</p><p><strong>Results: </strong>A total of 5 cases of synchronous GIST and intra-abdominal liposarcoma have been reported in the literature to date, with the most recent cases included in the present study.</p><p><strong>Conclusion: </strong>Further research is required to explain any possible correlation in the coexistence of these different neoplasms of the same origin. Meanwhile, R0 resection of both tumors remains the treatment of choice.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"2626635"},"PeriodicalIF":1.5,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39416375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer. 向靶向治疗的过渡改善了同步转移性肾细胞癌患者的预后并增加了药物治疗的利用率。
IF 1.5 Q4 ONCOLOGY Pub Date : 2021-08-12 eCollection Date: 2021-01-01 DOI: 10.1155/2021/5237695
Lauri Laru, Hanna Ronkainen, Markku H Vaarala

Since the introduction of targeted therapies (TTs) for metastatic renal cell cancer (mRCC) in 2005, a limited amount of epidemiological data on efficacy of modern drug therapies for synchronous mRCC has been published. We present a comprehensive nationwide cohort including all cases of primarily metastasized renal cell cancer among adults diagnosed between 2005 and 2010, based on data from the Finnish Cancer Registry and patient records from treating hospitals. Applied treatment protocols and survival outcomes were analyzed. A total of 977 patients were included in the analysis; 499 patients were diagnosed between 2005 and 2007 and 478 patients were diagnosed between 2008 and 2010. The median overall survival (OS) was 8.80 months (95% confidence interval (CI): 7.60-10.02). The median OS of the patients diagnosed at the latter era was significantly better (11.1; 95% CI: 8.8-13.4 vs. 7.0; 95% CI: 5.7-8.3 months, p ≤ 0.001). A total number of 524 (53.8%) patients received drug therapy. Altogether, TTs including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors (mTORi), and vascular endothelial growth factor inhibitor covered 331 (63.2%) of first-line treatments, whereas interferon and its combinations with chemotherapy were used for 186 (35.5%) patients. The median OS rates for TT and interferon as first-line therapy groups were 19.9 (16.9-22.8) and 14.9 (12.3-17.4) months, respectively. The OS for patients who did not receive drug therapy after cytoreductive nephrectomy was dismal. We found that the OS estimate of mRCC patients in Finland has improved since the introduction of tyrosine kinase inhibitors. However, the prognosis remains poor for frail, elderly patients with an impaired performance status.

自2005年针对转移性肾细胞癌(mRCC)引入靶向治疗(tt)以来,关于现代药物治疗同步mRCC疗效的流行病学数据有限。基于芬兰癌症登记处的数据和治疗医院的患者记录,我们提出了一个全面的全国队列研究,包括2005年至2010年间诊断的所有成人原发性转移性肾细胞癌病例。分析应用的治疗方案和生存结果。共有977例患者被纳入分析;2005年至2007年期间诊断出499名患者,2008年至2010年期间诊断出478名患者。中位总生存期(OS)为8.80个月(95%可信区间(CI): 7.60-10.02)。后一时期诊断的患者的中位OS明显更好(11.1;95% CI: 8.8-13.4 vs. 7.0;95% CI: 5.7-8.3个月,p≤0.001)。共524例(53.8%)患者接受药物治疗。总的来说,包括酪氨酸激酶抑制剂、哺乳动物雷帕霉素靶点抑制剂(mTORi)和血管内皮生长因子抑制剂在内的TTs治疗覆盖了331例(63.2%)一线治疗,而干扰素及其联合化疗用于186例(35.5%)患者。TT和干扰素作为一线治疗组的中位OS率分别为19.9(16.9-22.8)和14.9(12.3-17.4)个月。对于细胞减减性肾切除术后未接受药物治疗的患者,OS是令人沮丧的。我们发现芬兰mRCC患者的OS估计自引入酪氨酸激酶抑制剂以来有所改善。然而,对于身体虚弱、表现不佳的老年患者,预后仍然很差。
{"title":"Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer.","authors":"Lauri Laru,&nbsp;Hanna Ronkainen,&nbsp;Markku H Vaarala","doi":"10.1155/2021/5237695","DOIUrl":"https://doi.org/10.1155/2021/5237695","url":null,"abstract":"<p><p>Since the introduction of targeted therapies (TTs) for metastatic renal cell cancer (mRCC) in 2005, a limited amount of epidemiological data on efficacy of modern drug therapies for synchronous mRCC has been published. We present a comprehensive nationwide cohort including all cases of primarily metastasized renal cell cancer among adults diagnosed between 2005 and 2010, based on data from the Finnish Cancer Registry and patient records from treating hospitals. Applied treatment protocols and survival outcomes were analyzed. A total of 977 patients were included in the analysis; 499 patients were diagnosed between 2005 and 2007 and 478 patients were diagnosed between 2008 and 2010. The median overall survival (OS) was 8.80 months (95% confidence interval (CI): 7.60-10.02). The median OS of the patients diagnosed at the latter era was significantly better (11.1; 95% CI: 8.8-13.4 vs. 7.0; 95% CI: 5.7-8.3 months, <i>p</i> ≤ 0.001). A total number of 524 (53.8%) patients received drug therapy. Altogether, TTs including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors (mTORi), and vascular endothelial growth factor inhibitor covered 331 (63.2%) of first-line treatments, whereas interferon and its combinations with chemotherapy were used for 186 (35.5%) patients. The median OS rates for TT and interferon as first-line therapy groups were 19.9 (16.9-22.8) and 14.9 (12.3-17.4) months, respectively. The OS for patients who did not receive drug therapy after cytoreductive nephrectomy was dismal. We found that the OS estimate of mRCC patients in Finland has improved since the introduction of tyrosine kinase inhibitors. However, the prognosis remains poor for frail, elderly patients with an impaired performance status.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"5237695"},"PeriodicalIF":1.5,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39334829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
International Journal of Surgical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1